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Type 2 Diabetes (T2D) is a chronic disease arising from the development of insulin absence
or resistance within the body, and a complex interplay of environmental and genetic
factors. The incidence of T2D has increased throughout the last few decades, together
with the occurrence of the obesity epidemic. The consideration of variants identified by
GenomeWide Association Studies (GWAS) into risk assessment models for T2D could aid
in the identification of at-risk patients who could benefit from preventive medicine. In this
study, we build several risk assessment models, evaluated with two different classification
approaches (Logistic Regression and Neural Networks), to measure the effect of including
genetic information in the prediction of T2D. We used data from to the Original and
the Offspring cohorts of the Framingham Heart Study, which provides phenotypic and
genetic information for 5245 subjects (4306 controls and 939 cases). Models were built
by using several covariates: gender, exposure time, cohort, body mass index (BMI), and
65 SNPs associated to T2D. We fitted Logistic Regressions and Bayesian Regularized
Neural Networks and then assessed their predictive ability by using a ten-fold cross
validation. We found that the inclusion of genetic information into the risk assessment
models increased the predictive ability by 2%, when compared to the baseline model.
Furthermore, the models that included BMI at the onset of diabetes as a possible effector,
gave an improvement of 6% in the area under the curve derived from the ROC analysis.
The highest AUC achieved (0.75) belonged to the model that included BMI, and a genetic
score based on the 65 established T2D-associated SNPs. Finally, the inclusion of SNPs
and BMI raised predictive ability in all models as expected; however, results from the AUC
in Neural Networks and Logistic Regression did not differ significantly in their prediction
accuracy.
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INTRODUCTION
Type 2 Diabetes (T2D) is one of the fastest growing diseases in
the United States and other developed nations (Nugent, 2008;
Hu, 2011). In the last three decades, the number of Americans
diagnosed with diabetes has tripled (from 5.6 to 20.9 million),
making this a public health concern (CDC (Center for Disease
Control), 2013). T2D is a chronic metabolic disease, character-
ized by high levels of glucose in the blood, and frequently caused
by a deficiency of insulin secretion and/or the development of
insulin resistance (the inability of cells to respond to the insulin).
If not treated properly, it can produce kidney failure, blindness,
and circulatory problems. (Manzella, 2007; Buijsse et al., 2011;
Abbreviations: T2D, Type 2 Diabetes; AUC, Area Under the receiver operating
Curve; GS, Genetic Score; BMI, Body Mass Index; LR, Logistic Regression; NN,
Neural Network; OR, Odds Ratio.
Hu, 2011; Sanghera and Blackett, 2012). The interplay of envi-
ronmental (i.e., sedentary life, obesity, lack of exercise, poor diet)
and genetic factors (i.e., familial contribution), contribute to the
etiology and epidemy of T2D, in addition to an estimated heri-
tability of 26% (Poulsen et al., 1999). Since 2007, Genome Wide
Association Studies known as GWAS, have identified and con-
firmedmore than 50 loci associated with the development of T2D
(Steinthorsdottir et al., 2007; Lindgren et al., 2009; Shu et al.,
2010; Voight et al., 2010; Morris et al., 2012). Several genes identi-
fied so far are involved in encoding proteins necessary for insulin
secretion, glucose metabolism, and beta-cell function, which are
components that enable insulin production and insulin receptor
activation in the body (Sladek et al., 2007; Steinthorsdottir et al.,
2007; Yasuda et al., 2008).
Previous studies that have included genetic profiling and scores
in T2D preventive models, have shown only a slight increase in
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predictive ability. Generally, the use of genetic variants provides
a small contribution in terms of prediction accuracy due to their
small effects, especially if compared to the use of age and clini-
cally measured variables, such as BMI, and triglyceride levels and
known risk factors for this disease (Saxena et al., 2007; Lyssenko
et al., 2008; Voight et al., 2010; Vazquez et al., 2012). As of today,
while there is excitement with the possibility of a more person-
alized medicine, medical professionals do not consider genotypic
information as a variable in assessing patients’ risk of developing
T2D (Katsios, 2010; Lyssenko and Laakso, 2013). In several stud-
ies where risk assessment models have been built and tested, a
few deficiencies have been noticed that could possibly have influ-
enced their models’ predictive ability. Such deficiency may arise
due to the use of a model that so far does not capture the com-
plexity of polygenic signals and their interaction with covariates.
In addition, an ideal risk assessment model would incorporate the
interplay of a substantial number of small-effect genes and sev-
eral phenotypic variables (e.g., BMI) related to the development
of T2D in order to get a more realistic and precise prediction
(Lindstrom and Tuomilehto, 2003). However, by incorporating
other phenotypes (also heritable) into the risk assessment mod-
els, pleiotropic genetic effects shared by both traits could be
explained. BMI is an easy to measure phenotype, highly associ-
ated to diabetes and obesity and shown to be a strong predictor of
diabetes (Lyssenko et al., 2008; Meigs et al., 2008). Nevertheless,
it is possible that after accounting for BMI, the inclusion of SNP
variants associated to T2D, may not improve prediction accuracy
any further. However, this is an unanswered question.
To address these problems, we applied two statistical mod-
els (logistic regression, and a neural network) to data from the
Framingham Heart Study, and incorporated 65 SNPs that are
confirmed to be associated with T2D (Morris et al., 2012) to esti-
mate genetic and non-genetic effects in the prediction of T2D.
Since non-genetic factors play a predominant role in whether
genetically predisposed individuals progress on to T2D (Poulsen
et al., 1999), we considered including BMI information at the
onset of T2D, and importantly including genetic by BMI inter-
actions in the predictions of T2D.
MATERIALS AND METHODS
DATA
Our data set (n = 5239) came from the FraminghamHeart Study
which followed participants over seven decades and collected
information from bi-yearly physical and blood examinations. Our
sample was composed of 2378 females and 2861 males from the
Original and Offspring cohorts; where 4300 are controls and 939
subjects are cases. Diagnosis of T2D for subjects varied by cohort.
In the Original cohort, the presence of T2D was diagnosed with a
blood glucose level greater than or equal to 200 mg/dL; however,
for the offspring cohort, diabetes was diagnosed if fasting glucose
levels were equal or greater to 125mg/dL (NCBI, 2006, 2008).
We also examined 65 SNPs that were found to be associated
with T2D as listed in Morris et al. (2012). Since only 20 of the 65
SNPs were genotyped by the Affymetrix 500K chip in our sample,
genotype imputation was performed for the missing genotypes of
the SNPs by using the IMPUTE2 software (Howie et al., 2011).
Missing information per SNP was imputed with a mean accuracy
of 0.94. The imputation accuracy for all the imputed SNPs can be
seen in Table A in Supplementary Materials.
MODELS
In this section we will present the response variable, the set of
predictors, and the genetic covariates used to build the T2Dmod-
els. Subsequently, the parametric and non-parametric methods,
Logistic Regression (LR) and Neural Network (NN), respectively,
will be introduced and finally, we will detail a series of nested
models that incorporate BMI and genetic components consisting
of the 65 SNPs (Morris et al., 2012).
Set of response and predictor variables
Disease status of the participants was coded with a binary
response variable y(yi = 0 for absence and yi = 1 for presence
of T2D in the ith subject). A group of covariates was selected
based on the association with T2D (P < 0.01) and these were:
cohort (ci), a dummy variable indicating whether the subject i
belongs to the Original or Offspring cohort; age at last contact (li)
73.91 ± 11.74 (mean ± s.d.), was included to control for differ-
ent exposure time or observational period; the first two principal
components (PC1, PC2) derived from a set of 1000 European
ethnicity-informative SNPs (Drineas et al., 2010), and gender (si),
also coded with an indicator variable, with this set of co-variables
we generated a baseline model that is not influenced by genetic
effects. Each one of the risk assessment models was extended by
incorporating the body mass index (BMI, bi) at diabetes onset in
the case of diabetics and the last observed BMI for non-diabetics,
which served as a measure of obesity [bi (mean ± s.d.) = 27.75 ±
5.38]. In some models, the SNPs were incorporated either by
directly including the 65 SNPs or indirectly by a genetic score (GS)
calculated as the count of risk alleles presents on each subject per
SNP
(
GSi = ∑65j=1 xij; xij = {0, 1, 2}
)
. Where xij are the count of
risk alleles in the jth SNP for the ith subject. Risk alleles for the
inputted SNPs were given by the expected allele count xij being
this a continuous number ranging from [0, 2].
Logistic regression
The probability of diabetes peculiar to subject ith was given by a
linear predictor with a logit link (Dobson, 2002) in the following
form:
pi = E
(
yi|·
) = exp (ηi)
1 + exp(ηi) (1)
where E
(
yi|·
)
is the expected value for the diabetes status
(
yi
)
; pi
is the subject-specific probability of developing T2D given a set
of covariates for subject i and exp( · ) is the exponential func-
tion. The linear predictor (ηi) for a model built with only the
non-genetic predictor variables is described in equation (2) and
obtained as follows:
ηi = α0 + α1ci + α2si + α3bi + α4li (2)
where α0 is an intercept common to all observations, plus a
regression on the “fixed effects”; and α1 to α4 are the correspond-
ing regression coefficients or effects, for each one of the included
variables.
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Neural network
Bayesian Regularized Neural Network is a machine learning algo-
rithm that is suited for classification problems (Shekhar and
Amin, 1992; Neal, 1996; Gianola et al., 2011; Pérez-Rodríguez
et al., 2012). The Neural network aims to reduce the errors in
the training set, adjust the parameters and to respond properly
to novel inputs. One of the simplest neural networks is composed
of three layers: the input layer which consists of the input of all
the covariates for each one of the subject’s xij (i = 1 . . . 5245; j
is the quantity of covariates included per model) the hidden layer
that contains s neurons; and the output layer. Each input connects
to each one of the neurons creating an unknown weight wi for
each input. This inner product between the weights and the input
vector in each neuron of the hidden layer is given by equation:
uki = b0 +
65∑
j= 1
βjkxij, k = 1, . . . , s (neurons) , (3)
where uki in the hidden layer is transformed by applying an acti-
vation function.We used the tangent hyperbolic function: g (a) =
exp(2a)−1
exp(2a)+1 , which maps the inputs into the closed interval [−1,
1]. The output from each of the neurons is combined linearly
zi = μ +∑sk=1 wkg(uki) and finally transformed by applying the
function h (a) = 11+exp(−a) , which maps the inputs into an open
interval (0, 1), so that the output can be interpreted as a prob-
ability, that is yi = h(zi). Since the activation function can be a
nonlinear function, it allows the classifier to capture non-linear
effects.
Neural network models were fitted using the Bayesian
approach (MacKay, 1992) implemented in the Software for
Flexible Bayesian Modeling (FBM) written by Neal (1996)
which is available freely at www.cs.toronto.edu/∼radford/
fbm.software.html. For our analyses, a total of 6 neurons were
included in the hidden layer to reduce the computational burden,
since the results with 9 neurons yielded almost identical results.
Sequence of models
Six models were built, with the aim of evaluating the genetic
effects of the 65 variants associated to T2D as risk factors. Our
starting point was a Baseline model (BASE), which is composed
of only the non-genetic covariates or fixed effects: cohort, age at
last contact, gender and principal components. BASEBMI extends
model BASE by incorporating BMI in the set of predictors. Since
BMI co-varies with T2D, is reasonable to think that pleiotropic
effects may exist. Subsequently, we generated clinical models that
included genetic information. GEN65 extends BASE by incor-
porating the 65 SNPs associated to T2D; each SNP contains the
count of risk alleles {0, 1, 2}. The GENS extends BASE model
by adding the Genetic Risk Score (GS) consisting of the sum
of all variants that increase diabetes risk. To test whether there
are genetic effects on T2D after accounting for BMI, models
GENSBMI and GENBMI are extensions of the model of GENS
and GEN65, respectively, including BMI. Finally, GENBMI was
also extended accommodating SNPs by BMI interactions, into
a model called GENBSNPs×BMI. Table 1, shows the components
inside of each one of the models tested.
Estimated effects and confidence intervals
The estimated effects of gene markers and other covariates for
the risk of T2D were calculated and displayed in terms of
Odds Ratio (OR). The BASE model was used to estimate the
effects for all the non-genetic covariates. In addition P-values
were used to discriminate SNPs association to T2D and a 95%
Confidence Interval of the OR was built to determine the statis-
tical significance of the association between the response and the
predictors.
PREDICTIVE ABILITY
To evaluate the risk assessment models, a 10-fold cross-validation
was used to compare the accuracy of their respective predictions.
Each of the subjects within the data was assigned randomly to
the 10 folds. The testing sample consisted of a subset of 1/10th of
the data, and training would take the rest of the sample in order
to achieve an optimal predictive model. Predictive ability of the
models was assessed with the Receiver Operating Characteristic
Curve (Fawcett, 2006), using the R package “pROC” (Robin et al.,
2013), in order to obtain their Area Under a Curve (AUC), also
referred as C-Statistic.
RESULTS
DESCRIPTIVE STATISTICS
The characteristics of the 5245 subjects are described and sum-
marized in Table 2. More than half of the sample were females
(n = 2864), and only 18% of the overall subjects were diabetic.
Within the data set, BMI (mean± standard deviation) for diabet-
ics was 29.9 ± 6.0, and healthy subjects 27.3 ± 5.1. According to
the subjects BMI indexes, 28.2% of the observed subjects demon-
strated to be obese (n = 1482) and 67.4% of the sample were
overweight, while the rest were classified as normal. The mean
observed age at which sample subjects acquired T2D was 63 years
old. A reduction in the proportion of incidences of T2D can be
seen in the Offspring cohort since the subjects of the Original
cohort were observed during a longer time when compared to the
Offspring cohort.
GENETIC SCORE
GS is a subject specific count of all the risk alleles in each one
of the SNPs reported to be associated with risk of T2D. Table 3
shows a summary of the GS for both control and cases. GS ranged
Table 1 | Description of the model’s components.
Model components
Model Covariates (age, BMI 65 Genetic
name gender, PCs, cohort SNPs score
and exposure time)
BASE 
BASEBMI  
GEN65  
GEN65BMI   
GENS  
GENSBMI   
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from 52 to 86, which indicates that each individual had at least
one risk allele for T2D in almost every SNP. Individuals with a
high genetic score presented a greater cumulative incidence of
T2D, in comparison to subjects with a low risk score.
ESTIMATED EFFECTS
NN is a classifier that yields multiple estimated effects (depending
on the number of neurons), which complicates the interpretation
of the results. For that reason, estimates shown in this section are
results from the Logistic Regression model.
Table 4 shows the estimated Odds Ratio for the significant
covariates in all models. If these covariates are not augment-
ing T2D risk, we would expect an OR estimate and both limits
of the 95% confidence interval to include 1.0. All covariates
except the Principal Components were significantly associated
to diabetes (P < 0.01). Fixed effects estimates across the models
Table 2 | Descriptive statistics of the sample (n = 5245)*.
Covariates Diabetics Non-diabetics
Original Cohort (n = 1497) 30.2% (452) 69.8% (1045)
Offspring Cohort (n = 3742) 13.0% (487) 87% (3255)
Males 20.6% (489) 79.5% (1892)
Females 15.7% (450) 84.3% (2414)
BMI (mean ± s.d.) 29.9 ± 5.9 27.3 ± 5.1
Exposure Time (mean ± s.d.) 78.8 ± 10.6 72.9 ± 11.8
*Frequency of subjects per division are enclosed between parenthesis (n).
Table 3 | Genetic score frequencies per quartile.
Genetic Score Frequencies by diabetes status
Quartiles Non-diabetic, Diabetics,
percentage (n) percentage (n)
< 66.32 86% (1132) 14% (182)
66.32 ≤ GS < 69.55 85% (1108) 15% (199)
69.55≤ GS < 72.75 82% (1072) 18% (236)
≥72.75 75% (992) 25% (322)
were consistent for each of the covariates (i.e., the inclusion or
exclusion of effects in the model produced very little variation
of the estimated effects in the remaining effects in the model).
Therefore, describing one model (GENSBMI) suffices to under-
stand the effect of the covariates in the prediction of diabetes.
For GENSBMI, gender had an OR = 0.60 which implies a much
lower risk of developing T2D in women when compared to men.
The Cohort’s odds ratio (OR = 0.45), implies a lower risk of
T2D inOffspringmembers in comparison to theOriginal Cohort.
Exposure time had an OR of 1.03, resulting in a 3% increase in
risk of development for every year of exposure. The OR for the
Genetic Score is approximated to 1.1, which implies an increase
in risk of developing T2D, with the increase in value of the genetic
score. The OR for BMI was 1.13 in the models that included BMI.
This value demonstrates there is a 13% increment in risk of T2D
when increasing 1 kg/m2 in BMI.
SNP ESTIMATED EFFECTS
Table 5 provides the P-value of the 21 SNPs that gave a statistical
association with T2D in our study; we also present the P-value
of those SNPs, in association to BMI and WHR as reported in
the Giant Consortium (Heid et al., 2010; Speliotes et al., 2010).
Only four SNPs found in the genes GLIS3, PTPRD, TCF7L2,
and TSPAN8; had an association with a P-value less than 0.001.
The SNPs: rs11717195, rs17301514, rs4299828, rs11063069, and
rs10842994 have a P-value less than 0.1, therefore suggested as
possible risk genetic variants. A total of three SNPs, each pertain-
ing to a different gene, were found to be associated toWHR. These
genes were: GCKR (Glucokinase Regulatory Protein), IGF2BP2
(Insulin-Like Growth Factor 2 MRNA Binding Protein 2), and
PTPRD (protein tyrosine phosphatase receptor D). In addition,
two SNPs strongly associated to BMI, were located in the genes
IRS1 (Insulin Receptor Substrate 1) and TCF7L2 (Transcription
Factor 7-Like 2).
INTERACTION WITH BMI
Our results suggest SNP by BMI interaction with five SNPs
at a P < 0.05, and 8 genes SNPs with P < 0.1. These results
along with the estimated OR are provided in Table 6, for all
SNPs. The location of the interacting SNPs are in/near the
following genes: the Transcription Factor 7 like 2 (TCFL2),
Table 4 | Estimated odd ratios (95% C.I) for covariates in risk assessment models**.
Covariates BASE BASEBMI GEN65 GEN65BMI GENS GENSBMI
Gender 0.63
(0.54–0.73)
0.61
(0.52–0.71)
0.61
(0.53–0.72)
0.59
(0.51–0.70)
0.62
(0.53–0.72)
0.60
(0.51–0.70)
Cohort 0.52
(0.42–0.64)
0.45
(0.36–0.56)
0.51
(0.40–0.64)
0.45
(0.35–0.57)
0.52
(0.42–0.65)
0.45
(0.36–0.57)
ExposureTime 1.03
(1.02–1.04)
1.04
(1.03–1.05)
1.03
(1.02–1.04)
1.04
(1.03–1.05)
1.03
(1.02–1.04)
1.04
(1.03–1.05)
GS – – – – 1.07
(1.05–1.08)
1.07
(1.05–1.09)
BMI – 1.12
(1.11–1.14)
– 1.13
(1.11–1.15)
– 1.13
(1.11–1.14)
**Odds Ratio for the genetic score are only reported for the only two models where it was included.
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Table 5 | P-value for the evaluated SNPs and their reported P-values
for association to WHR and BMI in the giant consortium.
SNP Gene P-value BMI WHR
P-value*** P-value***
rs780094 GCKR 0.0029 0.093 0.00026
rs2943640 IRS1 0.0418 0.006 0.60
rs11717195 ADCY5 0.0508 0.049 0.10
rs4402960 IGF2BP2 0.0131 0.020 0.003
rs17301514 ADIPOQ 0.0609 0.155 0.450
rs7756992 CDKAL1 0.0337 0.070 0.230
rs4299828 IRS4 0.0991 0.474 0.530
rs3734621 KIF6 0.0378 0.082 0.190
rs849135 JAZF1 0.0418 0.057 0.120
rs10758593 GLIS3 0.000532 0.790 0.190
rs16927668 PTPRD 0.0012 0.999 0.006
rs10811661 CDKN2B 0.0050 0.891 0.110
rs7903146 TCF7L2 1.23E-06 0.00024 0.310
rs163184 KCNQ1 0.0264 0.887 0.590
rs10830963 MTNR1B 0.02918 0.211 0.42
rs11063069 CCND2 0.066935 0.127 0.49
rs10842994 KLHDC5 0.065763 0.367 0.53
rs7955901 TSPAN8/ LGR5 0.000192 0.836 0.18
rs12427353 HNF1A 0.02744 0.746 0.61
rs7177055 HMG20A 0.014363 0.051 0.23
rs11651052 TCFL4 0.008092 – –
***P-values of BMI and waist-to-hip ratio (WHR) as reported by GIANT consor-
tium. (Lindgren et al., 2009).
Gastric Inhibitory Polypeptide Receptor (GIPR), Growth Factor
Receptor-Bound Protein (GRB14), G1/S-Specific Cyclin D2
(CCND2), Transducin-Like Enhancer of Split 1 (TLE1), Cartilage
Intermediate Layer Protein 2 (CILP2) and HNF1 homeobox B
(HNF1B). Genes CILP2, HNF1B, and HMGA2, were confirmed
to have an association with BMI (P < 0.001). We did not detect
any significant interaction in the model where genetic effects were
incorporated as a Genetic Score (i.e., GENSBMI).
PREDICTIVE ABILITY
Predictive ability of themodels was evaluated with a ten-fold cross
validation and measured in terms of AUC. Values of the AUC
in cross validation, for all risk assessment models in the Logistic
Regression and Neural Networks, are reported in Table 7. In addi-
tion, ROC Curves for each risk assessment model tested with the
Neural Networks, can be found in Table B the Supplementary
Material.
The AUC of the logistic regression in the BASE model was
0.6658 and 0.666, in the LR and NN models respectively. The
incorporation of BMI (BASEBMI), increased the AUC to 0.739 and
0.735 for LR and NN, respectively. Also, accounting for genetic
markers in GEN65, increased the predictive ability of the mod-
els by approximately 2%, when compared to the baseline factors
alone. We further analyzed the extent to which the predictive
accuracy could be improved by adding BMI to the GEN65 model
and achieved a discriminative value of 0.745 and 0.741 (LR and
NN, respectively), resulting in an increase of approximately 7%.
Table 6 | Odds Ratio of SNP by BMI interactions of highest
significance.
SNP Gene Odds Ratio (95%C.I) P-value
rs8108269 GIPR 1.02 (1.0–1.05) 0.0896
rs13389219 GRB14 1.02 (1.00–1.04) 0.0421
rs11063069 CCND2 1.02 (0.99–1.05) 0.0870
rs7903146 TCF7L2 1.02 (1.00–1.04) 0.0404
rs2796441 TLE1 0.97 (0.95–1.00) 0.0231
rs10401969 CILP2 1.08 (1.03–1.13) 0.001906
rs11651052 HNF1B 0.95 (1.03–1.13) 0.000124
rs2261181 HMGA2 0.96 (0.93–0.99) 0.005184
Table 7 | Predictive ability of the models evaluated with the area
under the receiver operating curve (AUC).
Risk assessment models LR NN
BASE 0.6658 0.6666
BASEBMI 0.7393 0.7354
GEN65 0.6785 0.6786
GEN65BMI 0.7452 0.7411
GENS 0.6858 0.6857
GENSBMI 0.7495 0.7496
GENBSNPxBMI 0.7362 0.7432
Previous studies have shown a correlation between the increases
in weight and body mass with an increase in probabilities of
developing T2D. The incorporation of the genetic score after
accounting for BMI further increased AUC to 0.750 (i.e., the
GENSBMI model, for both LR and NN). A difference of approx-
imately 8% in predictive ability was observed in the GEN65BMI
model, when compared with the baseline model (see Table 7).
The inclusion of the interaction of the SNPs with BMI in T2D,
gave an AUC of 0.7362 in the GENBSNPxBMI model; with a 0.7%
increase when modeled in the Neural Network. Both statistical
methods yielded approximately the same AUC. Predictive values
show that when strong genetic variants related to T2D are chosen,
they substantially improve prediction of risk for T2D.
DISCUSSION
In this paper we investigated the effects of including genetic
information in preventive risk assessments for T2D, while using
different modeling approaches (LR andNN). The effect of includ-
ing genetic information was examined by adding 65 candidate
SNPs for T2D and computing a genetic score based on these SNPs.
Of the 65 SNPs analyzed, 7 SNPs that are located in 4 genes
(GLIS3, TCF7L2, LGR5, and PTPRD), showed a strong associ-
ation with Type 2 Diabetes. In addition, IGF2BP2 and GCKR
have been identified by several meta-analyses (Dupuis et al.,
2010; Heid et al., 2010; Speliotes et al., 2010; Morris et al.,
2012) as risk genetic variants for Type 2 Diabetes with effects
in WHR. The SNPs: rs780094, rs7756992, rs7955901 are in the
GCKR, CDKAL1, and LGR5 gene regions; with annotated func-
tions of insulin production, pancreatic cell growth, and glucose
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homeostasis, respectively. GLIS3 has been listed as a diabetes sus-
ceptibility gene due to its role in the generation of pancreatic beta
cells; an alteration in the expression of this gene could repress the
generation of beta cells, and may be involved in pancreatic dys-
function (Dupuis et al., 2010; Nogueira et al., 2013). TCF7L2 was
observed to have a relationship with BMI in both the DIAGRAM
and GIANT consortiums (Lindgren et al., 2009; Morris et al.,
2012). It has demonstrated to lower insulin secretion by affect-
ing β-cell responsiveness to insulin; it is also found in chromatin
regions in islets (Kiessling and Ehrhart-Bornstein, 2006; Sladek
et al., 2007; Lyssenko et al., 2008; Mccarthy and Zeggini, 2009).
The gene PTPRD (protein tyrosine phosphatase receptor type D)
provides a component needed to trigger the reactions for the link-
age of the insulin receptor to tissue. However, it was excluded
as a risk gene for Type 2 Diabetes by Bektas et al. (2001) since
none of the mutations did segregate with diabetes. IRS1 showed
an association with BMI through SNP-by-BMI interaction. This
genetic variant, with an increased interaction with multiple pro-
teins, has been associated with T2D and obesity, and could lead to
the development of insulin resistance (Rung et al., 2009; Caruso
et al., 2014).
When analyzing the effects of the inclusion of genetic variants
in the prediction of this disease, our results suggest that a vast
number of SNPs provide a modest enhancement in the predic-
tive ability of the models. Improvement of these discriminative
values, show that the added SNPs capture genetic risk. However,
when the interaction of the SNPs by environment (BMI) was
included in the model, no further increase was seen. The consis-
tency of AUC throughout the models, with the use of both Neural
Network and Logistic Regression, suggests that the use of differ-
ent statistical approaches neither aided nor reduced the predictive
ability of the models. The limitation in predictive accuracy seems
to be associated to factors other than the statistical model, such
as: the size of the training sample, the number of SNPs included
in the model, missing heritability issues and low heritability of
the trait. A few concerns about SNPs information, were observed.
The first pertains to the imputation uncertainty of the SNPs, since
it was not fully taken into account in our analyses. Nevertheless,
an alternative methods that consider imputation uncertainty are
proposed by Marchini and Howie (2010). Secondly, biases could
have been produced in the SNPs estimates due to family structure;
nevertheless, since the number of families within our sample is
large, it is considered to be of minor importance. In our sample
of 5245 subjects, 2073 subjects were aggregated from 495 fami-
lies, (these families contained subjects with at least one relative in
the sample), moreover, the size of these families was 4.19 ± 6.40
(mean ± s.d) members per family.
The most commonly identified covariates used in assessment
analyses that provide a high AUC (0.60–0.80) as a clinical base-
line model have been: age, high blood pressure, and glucose levels
between other covariates (Hu et al., 2001; Lyssenko et al., 2008;
Meigs et al., 2008; Cooke et al., 2012). Due to the small effects
and marginal change that genotyped data provides in risk pre-
diction, they have been used in only a few models to quantify
individual disease risk and thus to facilitate personalized manage-
ment of T2D risk. The ability and the effects of including genetic
information into risk prediction, have been widely studied but
are still limited. Previous risk assessments were SNPs associated
to T2D were included, slightly improved their predictive ability
when compared to baseline clinical covariates (Lyssenko et al.,
2008; Meigs et al., 2008; Van Hoek et al., 2008; Katsios, 2010; Bao
et al., 2013; Lyssenko and Laakso, 2013; Talmud et al., 2014). In
her study, Van Hoek et al. (2008), incorporated 18 SNPs, together
with age, sex, and BMI and achieved an AUC of 0.68, yielding
only a approximately 2% increase when compared to the base-
line model. Furthermore, Lyssenko et al. (2008), evaluated the
inclusion of a genetic score built with 16 SNPs; in addition to,
multiple clinical covariates and achieved a discriminative value
of 0.74. The addition of a modest amount of SNPs into risk pre-
diction was lately studied by Talmud et al. (2014), with the use
of 65 SNPs found by the DIAGRAM consortium, which were the
same used in this study. A genetic score and clinical covariates
such as: BMI, triglyceride levels and fasting glucose, altogether
with a large data set, resulted in an AUC of 0.75. This last result is
consistent with our results in the model GENSBMI. A limitation
of our study is that we did not take into account other clini-
cal variables that have shown some degree of association with
diabetes, such as triglyceride levels, high blood pressure, LDL or
HDL, which could have enhanced our results. The Framingham
Heart Study provides these variables, but there are missing values
in many exams and subjects. To avoid reducing sample size, we
only included BMI longitudinally (i.e., account for BMI at the first
diabetes record), and we found that genetic signal from the SNPs
is captured beyond what could be explained by the BMI. BMI esti-
mated effect on diabetes may result biased since we incorporated
BMI as the BMI at first diabetes diagnosis for diabetic subjects
and last BMI on record for healthy subjects. However, prelimi-
nary analysis (not included in the paper) show us that the effect
and their significance, for BMI and other covariables in the mod-
els, are insensitive to alternative ways to account for BMI, such as,
BMI at the first exam, or maximum BMI of the subjects observed
period. Despite our limitations, our study can provide important
remarks. The effect of genetic information in the improvement of
the prediction accuracy, was evaluated in our models by incorpo-
rating 65 SNPs both directly and into a genetic score. In addition,
we looked at the inclusion of gene-environment (BMI) and gene-
gene interaction into risk prediction. Also, a classical logistic
regression and a Neural Network (a non-parametric classification
algorithm) were explored.
Prevalence of T2D is highest among individuals with a BMI ≥
40 kg/m2 (Bays et al., 2007). The increase in central adiposity and
percent body fat is associated with an increased risk of T2D; how-
ever, not all obese or overweight patients develop T2D, and of
those who do, just a proportion is genetically predisposed. Our
results show, in agreement with the literature, that BMI serves as
a prediction enhancer for T2D. Predictive accuracy yielded bet-
ter estimates in the baseline model that included BMI; and this
was further improved when the genetic effect was also incorpo-
rated, giving an AUC difference of a approximately 8% when
compared to baseline. Interaction between BMI and the genes:
CILP2, HNF1B, and HMGA2 in relation to T2D, was found
and reported in Table 6. HNF1B is a homodimer in charge of
the nephron and pancreas development. Mutations in this gene
region could result in the development of diabetes. In addition,
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HMGA2 has transcriptional regulating factors which play a role
in adipogenesis and fat storage, inducing obesity.
In summary, this study confirmed the association of 21 genetic
variants with T2D. It was observed that individuals who have a
high genetic score may have increased probabilities of developing
Type 2 Diabetes. Also, accounting for genetic information, either
by including SNPs or a Genetic Score in the regression, led to an
improvement in prediction accuracy (AUC) of approximately 2%.
However, modeling strategies such as Neural Network or Logistic
Regression did not yield differences in terms of prediction. We
also showed that the inclusion of BMI into the risk assessment
models, improved the predictive accuracy by approximately 8%.
Furthermore, the risk assessment model yielded a modest incre-
ment in prediction accuracy when including genetic risk score,
even after accounting for BMI. This small improvement suggests
that there is still genetic signal involved in the development of
T2D, yet to be captured, that could produce effects beyond the
increase in BMI. In summary, marker information in addition to
commonly used baseline covariates such as BMI, could lead to an
overall modest improvement of predictive performance.
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